Skip Navigation

Jonathan L Kaufman, MD

Assistant Professor
Emory School of Medicine

Discovery and Developmental Therapeutics Program at Winship Cancer Institute

Associate Director
Hematology and Medical Oncology Fellowship Training Program

Associate Vice-Chair for Quality
Hematology and Medical Oncology Department

Dr. Kaufman received his medical degree from the Medical College of Georgia in Augusta, Georgia. He subsequently completed a residency in internal medicine and a fellowship in hematology and medical oncology at Emory University. Dr. Kaufman is an active clinical and translational researcher in the fields of multiple myeloma, lymphoma, and bone marrow transplant. He is involved in the American Society of Hematology and the American Society of Clinical Oncology. He has authored or coauthored more than 35 peer-reviewed manuscripts, book chapters, and abstracts. His work has been published in journals such as Blood, Leukemia, Clinical Cancer Research, Journal of Immunology, Cancer, and Clinical Lymphoma and Myeloma. He has served as a reviewer for Clinical Lymphoma and Myeloma, Bone Marrow Transplantation, Clinical Cancer Research and Leukemia. Dr. Kaufman has presented his clinical research on multiple myeloma at invited institutional lectures, as well as national and international Hematology and Oncology conferences. He is a member of the International Myeloma Working Group as well as the International Myeloma Society.

Full Clinical Bio >>

Research Interests

The goal of Dr. Kaufman’s research is to develop new treatments for patients with plasma cell disorder and lymphoma. His clinical research focuses on rapidly translating advances identified in laboratory models to patients. He was an investigator on the pivotal study of the combination of lenalidomide, bortezomib and dexamethasone (RVD) which has defined a new standard of care for patients with newly diagnosed myeloma. He is currently leading a trial in collaboration with investigators from MD Anderson and the Dana Farber Cancer Institute of adding vorinostat to RVD in newly diagnosed myeloma patients. In addition he works within several consortia including ECOG, MMRC and AMyC in order to conduct high impact clinical trials.


View publications on PubMed